Y
Yashar S. Niknafs
Researcher at University of Michigan
Publications - 41
Citations - 4261
Yashar S. Niknafs is an academic researcher from University of Michigan. The author has contributed to research in topics: Prostate cancer & Cancer. The author has an hindex of 19, co-authored 40 publications receiving 3259 citations.
Papers
More filters
Journal ArticleDOI
The landscape of long noncoding RNAs in the human transcriptome
Matthew K. Iyer,Yashar S. Niknafs,Rohit Malik,Udit Singhal,Anirban Sahu,Yasuyuki Hosono,Terrence R. Barrette,John R. Prensner,Joseph R. Evans,Shuang G. Zhao,Anton Poliakov,Xuhong Cao,Saravana M. Dhanasekaran,Yi-Mi Wu,Dan R. Robinson,David G. Beer,Felix Y. Feng,Hariharan K. Iyer,Arul M. Chinnaiyan +18 more
TL;DR: The lncRNA landscape characterized here may shed light on normal biology and cancer pathogenesis and may be valuable for future biomarker development.
Journal ArticleDOI
Rapid intraoperative histology of unprocessed surgical specimens via fibre-laser-based stimulated Raman scattering microscopy.
Daniel A. Orringer,Balaji Pandian,Yashar S. Niknafs,Todd C. Hollon,Julianne Boyle,Spencer Lewis,Mia Garrard,Shawn L. Hervey-Jumper,Hugh J. L. Garton,Cormac O. Maher,Jason Heth,Oren Sagher,D. Andrew Wilkinson,Matija Snuderl,Sriram Venneti,Shakti Ramkissoon,Kathryn McFadden,Amanda Fisher-Hubbard,Andrew P. Lieberman,Timothy D. Johnson,X. Sunney Xie,Jay Kenneth Trautman,Christian W. Freudiger,Sandra Camelo-Piragua +23 more
TL;DR: This work demonstrates the first application of SRS microscopy in the operating room by using a portable fibre-laser-based microscope and unprocessed specimens from 101 neurosurgical patients and builds and validated a multilayer perceptron based on quantified SRH image attributes that predicts brain-tumour subtype with 90% accuracy.
Journal ArticleDOI
The lncRNA landscape of breast cancer reveals a role for DSCAM-AS1 in breast cancer progression
Yashar S. Niknafs,Sumin Han,Teng Ma,Corey Speers,Chao Zhang,Kari Wilder-Romans,Matthew K. Iyer,Sethuramasundaram Pitchiaya,Rohit Malik,Yasuyuki Hosono,John R. Prensner,Anton Poliakov,Udit Singhal,Lanbo Xiao,Steven Kregel,Ronald F. Siebenaler,Shuang G. Zhao,Michael Uhl,Alexander R. Gawronski,Daniel F. Hayes,Lori J. Pierce,Xuhong Cao,Colin Collins,Rolf Backofen,Cenk Sahinalp,Cenk Sahinalp,Cenk Sahinalp,James M. Rae,Arul M. Chinnaiyan,Felix Y. Feng +29 more
TL;DR: It is shown that lncRNA-based profiling categorizes breast tumours by their known molecular subtypes in breast cancer, and the role of the top prioritized oestrogen receptor (ER)-regulated lncRNAs, DSCAM-AS1, is investigated.
Journal ArticleDOI
Oncogenic Role of THOR, a Conserved Cancer/Testis Long Non-coding RNA
Yasuyuki Hosono,Yashar S. Niknafs,John R. Prensner,John R. Prensner,Matthew K. Iyer,Saravana M. Dhanasekaran,Rohit Mehra,Sethuramasundaram Pitchiaya,Jean Tien,June Escara-Wilke,Anton Poliakov,Shih Chun Chu,Sahal Saleh,Keerthana Sankar,Fengyun Su,Shuling Guo,Yuanyuan Qiao,Susan M. Freier,Bui Huynh-Hoa,Xuhong Cao,Rohit Malik,Timothy M. Johnson,David G. Beer,Felix Y. Feng,Weibin Zhou,Arul M. Chinnaiyan +25 more
TL;DR: A novel ultraconserved lncRNA, THOR, which exhibits expression exclusively in testis and a broad range of human cancers, and which represents a novel class of functionally important cancer/testis lncRNAs whose structure and function have undergone positive evolutionary selection is functionally characterized.
Journal ArticleDOI
Targeting the MLL complex in castration-resistant prostate cancer.
Rohit Malik,Amjad Khan,Irfan A. Asangani,Marcin Cieślik,John R. Prensner,Xiaoju Wang,Matthew K. Iyer,Xia Jiang,Dmitry Borkin,June Escara-Wilke,Rachell Stender,Yi-Mi Wu,Yashar S. Niknafs,Xiaojun Jing,Yuanyuan Qiao,Nallasivam Palanisamy,Lakshmi P. Kunju,Pranathi Meda Krishnamurthy,Anastasia K. Yocum,Dattatreya Mellacheruvu,Alexey I. Nesvizhskii,Xuhong Cao,Saravana M. Dhanasekaran,Felix Y. Feng,Jolanta Grembecka,Tomasz Cierpicki,Arul M. Chinnaiyan +26 more
TL;DR: It is demonstrated that the mixed-lineage leukemia protein (MLL) complex, a well-known driver of MLL fusion–positive leukemia, acts as a co-activator of AR signaling, and is identified as a potential therapeutic target in advanced prostate cancer.